A rumor regarding Cytokinetics (CYTK) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, ...

Morgan Stanley has upgraded Cytokinetics (CYTK) to overweight from equal weight while lowering its price target. Read more ...

Fintel reports that on February 13, 2025, Morgan Stanley upgraded their outlook for Cytokinetics (NasdaqGS:CYTK) from ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Morgan Stanley analyst Jeffrey Hung upgraded Cytokinetics (CYTK) to Overweight from Equal Weight with a price target of $67, down from $70. The ...

Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Cytokinetics (NasdaqGS:CYTK) with a Buy ...

Cytokinetics has a 1-year low of $42.72 and a 1-year high of $81.36. The business’s fifty day moving average price is $48.32 and its two-hundred day moving average price is $52.34. Insider ...

In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare ...

Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – B. Riley boosted their FY2024 earnings per share estimates for Cytokinetics in a note issued to investors on Wednesday, February 5th.